CH
PTCT icon

Canton Hathaway’s PTC Therapeutics PTCT Stock Holding History

Canton Hathaway’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,100
Closed -$37K – 208
2019
Q3 		$37K Hold
1,100
– – 0.02% 136
2019
Q2 		$50K Hold
1,100
– – 0.03% 123
2019
Q1 		$41K Hold
1,100
– – 0.02% 130
2018
Q4 		$38K Buy
1,100
+400
+57% +$14.4K 0.02% 117
2018
Q3 		$33K Buy
+700
New +$29K 0.02% 115

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Canton Hathaway's PTCT Position: Q4 2019 in Review

Canton Hathaway sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 1,100 shares — an estimated $37K sold.

Canton Hathaway first reported a position in PTCT in Q3 2018 and held it in 5 quarters. The position peaked at $50K in Q2 2019. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

  • Canton Hathaway reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Canton Hathaway sold 1,100 PTC Therapeutics shares in Q4 2019, an estimated $37K.
  • Canton Hathaway first reported a position in PTC Therapeutics in Q3 2018 and held it in 5 quarters.
  • Canton Hathaway's PTC Therapeutics position peaked at $50K in Q2 2019.
  • 206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Canton Hathaway's 13F filing for Q4 2019, filed 10 Jan 2020.